Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Celera, a healthcare business delivering personalized disease management through a combination of products and services, has appointed Scott Bland as vice president of sales of its Berkeley HeartLab, or BHL, subsidiary. Mr Bland will report to Chris Hall, chief business officer of BHL.
Subscribe to our email newsletter
Mr Bland has been a regional director of sales at BHL, providing oversight to sales activities in the southeast of the US for the last two years.
Prior to joining BHL, Mr Bland was a regional business advisor for Allergen Pharmaceuticals, and he also held various sales and management positions in cardiovascular disease with Kos Pharmaceuticals before the company was sold to Abbott.
Chris Hall, chief business officer of Berkeley HeartLab, said: “Scott adds a tremendous wealth of experience in cardiovascular disease management to our team at Berkeley HeartLab. We’ve experienced substantial growth and expansion at BHL, and as a result there’s a need to strengthen our commercial infrastructure.
“This new position goes a long way toward achieving this, and with a strong customer focus and a deep knowledge of the cardiovascular disease industry, we think Scott is well positioned to lead our sales efforts to deliver on our vision of personalizing disease management.”